Enlarged heart
When scarring and remodeling continue unchecked, the chamber stretches and the pump weakens. This is the outcome the whole chain is oriented against — the reason the earlier phases matter.
In depth
The enlarged, weakened heart that unresolved inflammation can leave behind.
What drives it
Supports heart function increases it.
10.3390/v17040484 — phase three — where a recoverable illness becomes a permanent one. 'profibrotic cytokines and mediators released during acute myocarditis in susceptible individuals activate fibroblasts and recruit new fibroblast differentiation via endothelial mesenchymal transition leading to cardiac remodeling and dilated cardiomyopathy' (Mayo/Elsevier chapter — Viral Myocarditis and Dilated Cardiomyopathy: Mechanisms of Cardiac Injury, Inflammation, and Fibrosis). Scar is not muscle. It does not contract, and once laid down it stays. This is the step that decides whether the heart recovers its function OR keeps a permanent deficit. doi 10.3390/v17040484
Cardiac autoantibodies increases it.
The antibodies that mistake the heart for the virus — and predict what happens next. 'cross-reacting antibodies with auto-antigens have been found in patients with myocarditis and ARE indicative of progression to DCM', and cardiac auto-antibodies were shown to 'predict disease development in asymptomatic relatives' (pmc2519249 — Acute viral myocarditis). ⇒ this is the mechanism by which a past infection keeps damaging a heart long after the virus itself is gone.
Immunotherapy heart inflammation increases it.
A cause that did not exist twenty years ago, and it is the deadliest one. Cancer drugs that release the immune system's brakes can let it attack the heart. 'Inflammation of the heart muscle... resulting from ICI targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA4), programmed cell death protein 1 (PD1) and PD1 ligand 1 (PDL1) is an infrequent but potentially fatal complication' (PubMed 38982146 · doi 10.1038/s41568-024-00715-5 — Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart, Nat Rev Cancer 2024;24(8):540-553). The numbers ARE stark: 'the fatal rate is as high as 39.7%-50%, and our results indicate the fatal rate is 47.4%' (doi 10.3389/fimmu.2023.1275254 — Immune checkpoint inhibitor-associated myocarditis: a systematic analysis of case reports), and 'combination ICI regimens (anti-CTLA-4 plus anti-PD-1) carry an approximately five-fold higher risk' (doi 10.3389/fphar.2026.1845366 — Immune checkpoint inhibitor-related cardiotoxicity: a cellular pharmacology perspective). And it is growing: 'nearly 50% of all patients with cancer ARE eligible for treatment with ICIs'. doi 10.1038/s41568-024-00715-5
Vessel constrictor increases it.
The road from inflammation to a permanently enlarged heart. Quercetin 'offers cardioprotection against progression of experimental autoimmune myocarditis by suppression of oxidative and endoplasmic reticulum stress via ENDOTHELIN-1/MAPK signaling' — tested explicitly on whether it 'protects from the progression of EAM to dilated cardiomyopathy' (PMID 22145946 — Quercetin offers cardioprotection against progression of experimental autoimmune myocarditis by suppression of oxidative and endoplasmic reticulum stress via endothelin-1/MAPK signaling). ⇒ this is the step that decides whether the illness ends OR becomes permanent. PMID 22145946
Muscle cell scaffold reduces it.
It cuts the scaffold that holds the muscle cell together — and that is a mechanical route to an enlarged heart, not an inflammatory one. 'protease 2A inhibits host cell protein synthesis, cleaves host protein dystrophin, and may induce cardiomyopathy and cardiomyocyte apoptosis' (doi 10.1007/s10495-006-0013-0 — Chau DHW et al. Coxsackievirus B3 proteases 2A and 3C induce apoptotic cell death through mitochondrial injury and cleavage of eIF4GI, Apoptosis 2007;12:513-524). It was shown directly in heart cells: 'dystrophin and eIF4G-1 ARE cleaved during coxsackievirus B3 infection of cultured myocytes' — rat neonatal ventricular cardiomyocytes, by western blot (Nat Med — Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy). ⇒ dystrophin is the same protein whose inherited loss causes muscular dystrophy with heart failure. The virus produces an acquired version of a genetic disease. doi 10.1007/s10495-006-0013-0
The Virus’s Own Scissors increases it.
Proof of the hardest kind: put the virus's scissors in a heart with NO virus, and the heart fails. 'transgenic mice with cardiac-specific localization of protease 2A develop severe cardiac dysfunction and dilated cardiomyopathy. These findings suggest that inhibiting protease 2A activity might be an effective method to treat CVB3 infection' (pmc11125614 — Caboxamycin Inhibits Heart Inflammation in a Coxsackievirus b3-Induced Myocarditis Mouse Model). ⇒ NO infection. NO immune attack. Just the enzyme — and the heart enlarges and weakens anyway. It also cuts the cell's protein-making machinery: an agent that works here 'substantially decreased CVB3 VP1 production and cleavage of translation factor eIF4G1'.
What it drives
It reduces Cardiac output.
https://www.merckmanuals.com/professional/cardiovascular-disorders/cardiomyopathies/dilated-cardiomyopathy — phase three — where a recoverable illness becomes a permanent one. 'profibrotic cytokines and mediators released during acute myocarditis in susceptible individuals activate fibroblasts and recruit new fibroblast differentiation via endothelial mesenchymal transition leading to cardiac remodeling and dilated cardiomyopathy' (Mayo/Elsevier chapter — Viral Myocarditis and Dilated Cardiomyopathy: Mechanisms of Cardiac Injury, Inflammation, and Fibrosis). Scar is not muscle. It does not contract, and once laid down it stays. This is the step that decides whether the heart recovers its function OR keeps a permanent deficit.
Blends that modulate it
Each blend page names this pathway and carries the study behind its claim.
See it on the map
Open the causal map to follow this pathway upstream and downstream, arrow by arrow, each with its study.